Side-by-Side Comparison · 2026

Omiganan vs Tyrocidine

Omiganan vs Tyrocidine — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?

Omiganan
Antimicrobial Peptide

Omiganan (CLS001, MBI-226) is a synthetic analog of indolicidin, a bovine neutrophil AMP. It was developed for topical antimicrobial applications including acne vulgaris, catheter-site infection prevention, and rosacea....

Calculate Omiganan dose →
Tyrocidine
Antimicrobial Peptide

Tyrocidine A is a cyclic decapeptide component of tyrothricin, one of the first antibiotic mixtures produced commercially. Isolated from Bacillus brevis soil bacteria, tyrocidines are non-ribosomally synthesized peptides that disrupt bacterial membranes through a carpet mechanism...

Calculate Tyrocidine dose →
Key Parameters
Parameter Omiganan Tyrocidine
Category Antimicrobial Peptide Antimicrobial Peptide
Research Phase 3 (Completed) Preclinical
Half-Life Hours (topical) Short
Typical Dose 1-3% gel N/A (component of tyrothricin)
Frequency Twice daily N/A
Route Topical gel/cream Topical (historical)
FDA Status Not approved Not approved (part of historical tyrothricin)

Calculate doses for both

Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.

Frequently Asked Questions
What is the difference between Omiganan and Tyrocidine?
Omiganan: Omiganan (CLS001, MBI-226) is a synthetic analog of indolicidin, a bovine neutrophil AMP. It was developed for topical antimicrobial applications including acne vulgaris, catheter-site infection preve... Tyrocidine: Tyrocidine A is a cyclic decapeptide component of tyrothricin, one of the first antibiotic mixtures produced commercially. Isolated from Bacillus brevis soil bacteria, tyrocidines are non-ribosomally ...
Which has a longer half-life, Omiganan or Tyrocidine?
Omiganan half-life: Hours (topical). Tyrocidine half-life: Short.
Can you stack Omiganan and Tyrocidine?
Omiganan and Tyrocidine are in the same category and used together in research protocols. Always consult relevant literature and follow appropriate guidelines.

For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.